Figure 6.

BPC 157 improves vessel presentation following suprahepatic occlusion of the inferior vena cava (upper), and eliminates or attenuates increased nitric oxide and malondialdehyde levels (nmol/mg protein) in liver. Vessels were assessed as to whether they were (filled or cleared out at the stomach, and between the arcade vessels on the ventral side for 1 cm long segments of duodenum, jejunum and ascending colon, and between 10 vessels from the proximal to distal cecum. Assessment was made throughout the experiment, with the point (A) immediately before therapy considered to be 100%, at selected time points before (A) and after therapy (B, C and D) in rats with suprahepatic occlusion of the inferior vena cava at 5 (B), 10 (C) and 15 (D) minutes post-ligation (mean ± SD). The gross appearance of the tissue was recorded using a USB microscope camera (upper). Counteraction of the increased nitric oxide and malondialdehyde levels in liver (lower) at 15 min, 24 h and 48 h post-ligation. Treatment with 10 µg/kg BPC 157 (gary bars), 10 ng/kg BPC 157 (black bars), or saline (1 mL/rat; white bars) as a bath administration given at 1 min post-ligation. ^aP < 0.05 vs saline; ^cP < 0.05 vs healthy liver (H). NO: Nitric oxide; MDA: Malondialdehyde.